Celldex Therapeutics, Inc. (CLDX) EPS Estimated At $-0.12

October 13, 2018 - By Louis Casey

Analysts expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to report $-0.12 EPS on November, 6.They anticipate $0.02 EPS change or 14.29 % from last quarter’s $-0.14 EPS. After having $-0.11 EPS previously, Celldex Therapeutics, Inc.’s analysts see 9.09 % EPS growth. The stock increased 6.06% or $0.02 during the last trading session, reaching $0.42. About 1.03M shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 84.28% since October 13, 2017 and is downtrending. It has underperformed by 99.90% the S&P500.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Coverage

Among 2 analysts covering Celldex (NASDAQ:CLDX), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Celldex had 2 analyst reports since April 16, 2018 according to SRatingsIntel. The company was downgraded on Monday, April 16 by Cowen & Co. Cantor Fitzgerald maintained the stock with “Neutral” rating in Tuesday, April 17 report.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $68.23 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Another recent and important Celldex Therapeutics, Inc. (NASDAQ:CLDX) news was published by Nasdaq.com which published an article titled: “Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific …” on October 09, 2018.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.